

2004
Request for Research Proposals



**The Samuel Waxman Cancer
Research Foundation
1150 Fifth Avenue
New York, NY 10128**



SAMUEL WAXMAN CANCER RESEARCH FOUNDATION
1150 Fifth Avenue
New York, NY 10128
Tel: 212-241-1760
Fax: 212-426-2273

The Samuel Waxman Cancer Research Foundation, founded in 1975, is a non-profit organization dedicated to conducting basic, translational and clinical research on the causes of cancer with the goal of developing scientifically targeted cancer treatments. The Foundation funds research in the United States, Canada, China and England, trains scientists, fosters collaboration and is instrumental in organizing international conferences based on the premise that cancer is reversible.

Monies raised primarily have supported the Rochelle Belfer Chemotherapy Foundation Laboratory at The Mount Sinai School of Medicine in New York City and the Samuel Waxman Cancer Research Foundation Laboratory and the Joint Experimental and Clinical Cancer Research Center at the Shanghai Second Medical University in China.

This year the Foundation will continue the expansion of the scope of its research mission to encourage **interactive, high-quality research** with the intent of developing new therapies for cancer, through the understanding of the mechanism of the development of the disease. Invitations will be sent to the directors of major cancer research programs, requesting the submission of one application for the award from each institution. Up to three grants will be awarded in 2004.

Priority will be given to:

- Proposals addressing promising new areas of study, for which funding may serve as the first step in obtaining long term funding from the National Institutes of Health and other major granting agencies.
- Studies that will directly impact the understanding of the mechanisms of disease and/or the clinical treatment of individuals with cancer.
- Translational studies involving the clinical treatment of individuals with cancer.

The research must be in one of the following areas:

- A. Development of transcription based therapy-agents that defeat gene repression in cancer
- B. Development of new therapies/pathways to overcome defective differentiation and/or encourage selective death (apoptosis) of cancer cells

Experimental design options include:

- A. Modeling of human cancer in animals and the eventual use of the model for therapeutic trials (Example: Use of arsenic and retinoic acid in APL in mice)
- B. Research measuring parameters of molecular response of human cancer to therapies (Example: Use of chips to determine the genetics or proteomic change of tumor that do or do not respond to therapy)
- C. Pre-clinical or clinical trials with proof of principle surrogate markers

The grants will be for \$100,000/year with 15% additional for overhead for two years; a third year of funding will be allowed pending the approval of a progress report and a positive review by the Foundation's Scientific Advisory Committee.

The grantees will be required to present at an annual scientific review. In addition, the grantees will visit New York a second time during each year to meet with other groups funded by the Foundation. The grantees will be expected to be highly collaborative and freely make available reagents and information resulting from the research to other scientists supported by the Foundation. Our goal is an "interactive research institution without walls".

2004 RFA GUIDELINES

PRINCIPAL INVESTIGATORS MAY APPLY FOR:

- A two-year grant for up to \$200,000 (maximum of \$100,000 per year).
- Upon completion of two years, an applicant may receive a third year of funding for an approved project, which will be subject to review by a grants review committee.

TIME-LINE

Application Deadline	December 15, 2003
Review of Applications by Grants Review Committee	January 2004
Notification of Funding Decision By	January 15, 2004
Funding Begins	February 1, 2004

APPLICATION PROCEDURE

1. Applications should be completed according to the guidelines listed below.
2. Applicant must have faculty status and be a peer-reviewed NIH principal investigator.
3. Salary and fringe for the principal investigator can be included for an amount up to \$30,000.
4. Equipment expenses should not exceed \$10,000.
5. Indirect costs (overhead) are allowed for up to 15 percent of the grant request.
6. Institutional approval of human experimentation procedures and animal use must be provided.
7. Proposals are due no later than December 15, 2003.

APPLICATION GUIDELINES

1. Please submit an original application that is typed, single-spaced, with 12-point type and at least one-inch margins.
2. Each application should be accompanied with a cover letter from the research director of your institution indicating how the candidate was selected within your institution to apply to the SWCRF.
3. Please submit the materials listed below, in the order they are listed:
 - a. Cover sheet
 - b. Summary of the proposal and how it relates to the goals of the RFA (one page limit)
 - c. Specific aims and rationale (one page limit)
 - d. Background information (three page limit)
 - e. Research plan and methods (six page limit)
 - f. References (two page limit)
 - g. Budget (one page limit):
 - i. Personnel: Salaries & Wages, Consultant Costs (P.I. maximum of \$30,000)
 - ii. Equipment (Maximum of \$10,000)
 - iii. Supplies
 - iv. Animal Care
 - v. Other Costs
 - vi. Indirect Costs (Maximum of 15% of total grant request)
 - h. Attach NIH Biosketch
 - i. Attach NIH Other Support
The SWCRF project should not substantially overlap with other sources of support.

SUBMISSION

Please e-mail your application and mail one hard copy to:

ann.jackowitz@mssm.edu
Ann Jackowitz, Executive Director
Samuel Waxman Cancer Research Foundation
1150 Fifth Avenue
New York NY 10128

Send an original and e-mail of the complete application and all attachments postmarked by midnight of the receipt date listed below. The review schedule is as follows:

Timeline

Receipt Deadline	December 15, 2003
Review by Grants Review Committee members	January 2004
Review by Board of Trustees	January 2004
Applicant Notified/Funding	By January 15, 2004
Award Checks Issued	February 1, 2004
Year #1 Research Cycle	February 1, 2004-January 31, 2005

Late applications will not be accepted, and the receipt date will not be waived.

Review and Award

All applications are evaluated by the Samuel Waxman Cancer Research Foundation's Grants Review Committee, comprised of members of the Scientific Advisory Committee and independent outside reviewers. Final review and approval rests with the Board of Trustees. Funding of awards is based on the priority score awarded each application, the recommendations of the Grants Review Committee and the Scientific Advisory Committee, and the availability of funds. Funding will occur February 1, 2004.

Post-Award Administration

Administrative Requirements

Changes that require prior approval by SWCRF:

Budget

The budget can be managed on a modular basis and transfers among categories of less than \$25,000 can be done at the investigator's discretion. Re-budgeting of larger amounts requires prior approval from SWCRF.

Transfer to Another Institution

Grants may be transferred from one organization to another upon **prior written approval from SWCRF**. The Principal Investigator of the grant is responsible for submitting to SWCRF in a timely manner the following: a letter requesting transfer of the grant, the Principal Investigator's new address, and the address and contact person in the new grants administration office. SWCRF will notify the institution and the Principal Investigator in writing of approval. SWCRF must receive a written acceptance of the grant by an authorized official of the new organization. Payments will not be initiated to the new organization until a final financial accounting of all expenditures from the original institution and a letter acknowledging that the grant has been accepted by the transfer organization has been received by SWCRF.

Transfer to a New Principal Investigator

Grants may be transferred from one Principal Investigator to another upon **prior written approval from SWCRF**. When transfer from one Principal Investigator to another is desired, the original Principal Investigator must submit a request in writing that includes: 1) the reason for the requested change; 2) the justification of the ability of the proposed new investigator to complete the project; and 3) the biographical information section of the SWCRF application form and a complete curriculum vitae of the proposed new Principal Investigator. SWCRF will notify the Principal Investigator in writing of its decision.

Extension Without Additional Funds

The grant period may be extended for up to one year without additional funds upon **prior written approval from SWCRF**. Requests for extensions should be

submitted no less than two (2) months prior to the expiration of the grant period. SWCRF will notify the Principal Investigator in writing of its decision.

Other Requirements

Progress Report

At the end of the first year of any two-year grant the Principal Investigator must submit a progress report and abstracts, reprints, and manuscripts of research supported in whole or in part by SWCRF. If there are no published materials credited to the grant, the report should be no more than three (3) typed pages and include any progress made on the specific aims as outlined in the grant application or other relevant information illustrating the status of the grant. At the discretion of SWCRF, funds for the second year of the grant may be withheld based on the progress report.

Final Scientific Report

At the completion of the grant period, SWCRF requires a comprehensive scientific report that indicates the project's accomplishments. Two (2) copies of reprints, abstracts or manuscripts in press must be included with the final scientific report.

All final scientific reports must be submitted within sixty (60) days of the termination date of the grant.

Financial Report

A final report of expenditures must be submitted by the grantee institution within ninety (90) days of the termination of the grant, together with the refund of any unexpended balance. Unexpended funds from an existing grant may only be carried forward to a renewal or an extended grant term with the written permission of SWCRF.

SWCRF is not responsible for the over-expenditure of grant funds, for commitments against a grant not paid within sixty (60) days after termination, or for expenditures made before the starting date of a grant.

Publications

Publications resulting from research supported all or in part by SWCRF must contain the following acknowledgment: "Supported by a grant from the Samuel Waxman Cancer Research Foundation."

Grantees must provide two (2) reprints of all published research to SWCRF.

SWCRF's Annual Research Conference

Principal Investigators will be required to attend the annual Scientific Advisory Committee review Research Conference and present an oral and written research summary.

Cancellation

A grant may be cancelled by either party upon thirty (30) days written notice. In the event of cancellation by SWCRF, the grantee organization will be reimbursed for all costs incurred and all non-cancelled commitments. In the event of cancellation by the grantee organization, any unexpended or unobligated funds advanced by SWCRF shall be refunded to SWCRF.

Intellectual Property

By accepting the award, the applicant organization recognizes that intellectual property (log books, slides, etc.) belong to the Investigator. However, these can be photocopied for the applicant organization if required.

Patents

SWCRF recognizes that patentable inventions may be made in the course of research supported in whole or in part by SWCRF funds (collectively, "SWCRF Inventions"). "Made" when used in relation to any invention means the conception or first actual reduction to practice of such invention. SWCRF believes that it is generally desirable that SWCRF Inventions be brought into public use at the earliest possible time and that the patent and licensing processes may frequently be the most reasonable means to accomplish this goal. Accordingly, SWCRF asks that all inventions discovered under the auspices of the SWCRF be promptly reported to SWCRF in writing. Under certain circumstances, SWCRF would be available to assist and participate in the patenting process.

APPLICATION FOR A TRANSLATIONAL RESEARCH GRANT

**TO: Samuel Waxman Cancer
Research Foundation
1150 Fifth Avenue
New York, NY 10128**

Application is hereby made for a
Translational Research Grant

Total amount requested: \$ _____
Period: February 1, 2004 through January 31, 2006

DATE:

TITLE OF PROJECT:

PRINCIPAL INVESTIGATOR	OFFICIAL AUTHORIZED TO SIGN FOR INSTITUTION
Last name, first name, initial, degree	Last name, first name
Title	Name of institution
Social Security number	Street and number
Name of institution	City, state, zip code
Department and/or Division	Telephone (area code, number, extension); e-mail
Street and number	Title of official authorized to sign for applicant's institution
City, State, Zip Code	Signature of Official
Telephone, fax, email	
Signature of Principal Investigator	

*It is understood that each applicant, by the act of applying for a grant, agrees, if the grant is made, to abide by the Foundation's Grant Policies.

Office to whom funds should be directed:

Street and number, room number, building:

City, state, zip code: